bms204352 has been researched along with tacrolimus in 3 studies
| Studies (bms204352) | Trials (bms204352) | Recent Studies (post-2010) (bms204352) | Studies (tacrolimus) | Trials (tacrolimus) | Recent Studies (post-2010) (tacrolimus) |
|---|---|---|---|---|---|
| 49 | 1 | 12 | 17,757 | 2,319 | 6,661 |
| Protein | Taxonomy | bms204352 (IC50) | tacrolimus (IC50) |
|---|---|---|---|
| Bile salt export pump | Homo sapiens (human) | 7.18 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 0.58 | |
| Cytochrome P450 3A5 | Homo sapiens (human) | 0.385 | |
| Serine/threonine-protein kinase mTOR | Homo sapiens (human) | 0.0021 | |
| Peptidyl-prolyl cis-trans isomerase FKBP1A | Homo sapiens (human) | 0.2547 | |
| Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform | Homo sapiens (human) | 0.0148 | |
| Splicing factor 3B subunit 3 | Homo sapiens (human) | 0.0123 | |
| Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | 3.3 | |
| Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) | 3.7 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, TK; Ensom, MH; Kiang, TK | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
1 review(s) available for bms204352 and tacrolimus
| Article | Year |
|---|---|
UDP-glucuronosyltransferases and clinical drug-drug interactions.
Topics: Clinical Trials as Topic; Drug Interactions; Enzyme Activation; Enzyme Induction; Glucuronides; Glucuronosyltransferase; Humans; Pharmaceutical Preparations; Pharmacogenetics; Polymorphism, Genetic | 2005 |
2 other study(ies) available for bms204352 and tacrolimus
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |